featured
MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL: Long-Term Efficacy and ctDNA Analysis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
Blood 2024 Apr 15;[EPub Ahead of Print], M Fürstenau, A Giza, J Weiss, F Kleinert, S Robrecht, F Franzen, J Stumpf, P Langerbeins, O Al-Sawaf, F Simon, AM Fink, C Schneider, E Tausch, J Schetelig, P Dreger, S Böttcher, K Fischer, KA Kreuzer, M Ritgen, A Schilhabel, M Brüggemann, S Stilgenbauer, B Eichhorst, M Hallek, P CramerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.